Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Radiotherapy + Telaglenastat |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Radiotherapy | ||||
| Telaglenastat | CB-839 | Glutaminase Inhibitor 3 | Telaglenastat (CB-839) binds to and inhibits glutaminase, preventing the conversion of glutamine to glutamate, which results in a decrease in cell proliferation (PMID: 31980651). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KEAP1 dec exp | lung non-small cell carcinoma | sensitive | Radiotherapy + Telaglenastat | Preclinical - Cell culture | Actionable | In a preclinical study, Telaglenstat (CB-839) increased sensitivity of a KEAP1 knockdown non-small cell lung cancer cell line to radiotherapy in culture (PMID: 33071215). | 33071215 |
| KEAP1 loss | lung adenocarcinoma | sensitive | Radiotherapy + Telaglenastat | Preclinical - Cell culture | Actionable | In a preclinical study, Telaglenstat (CB-839) increased sensitivity of KEAP1 knockout non-small cell lung cancer cells to radiotherapy in culture, demonstrating increased cell death and DNA double-strand breaks (PMID: 33071215). | 33071215 |
| KEAP1 mutant | lung adenocarcinoma | sensitive | Radiotherapy + Telaglenastat | Preclinical - Cell culture | Actionable | In a preclinical study, Telaglenstat (CB-839) increased sensitivity of a non-small cell lung cancer cell line harboring a KEAP1 mutation to radiotherapy in culture (PMID: 33071215). | 33071215 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|